Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Genakumab in Chinese Healthy Volunteers
NCT04337437Phase 1Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of genakumab in juvenile idiopathic arthritis (JIA) (6 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Maximum observed serum Genakumab concentration at Day 113, Area under the serum Genakumab concentration-time curve at Day 113 and 1 more. Status: unknown.
02
Drugs
genakumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT04337437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337437.